Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Jakavi 10mg Tablet
Manufacturer/Marketed By : NOVARTIS INDIA LTD
$460.16 $437.15
Jakavi 10mg Tablet contains the active constituent ruxolitinib. It is an anticancer agent that belongs to the class of kinase inhibitors. It is used to treat myelofibrosis (a rare type...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
RUXOLITINIB
Active Pharmaceutical Ingredient
Jakavi 10mg Tablet
$460.16
$437.15
Jakavi 10mg Tablet contains the active constituent ruxolitinib. It is an anticancer agent that belongs to the class of kinase inhibitors. It is used to treat myelofibrosis (a rare type of bone marrow cancer that causes decreased blood cell production). It is also used to treat polycythemia vera (a type of blood cancer where the body produces too many red blood cells) in people who are resistant or cannot be treated successfully with other medication (hydroxyurea). The medicine is also indicated to treat acute graft versus host disease (a complication of transplant procedure that replaced diseased bone marrow with healthy bone marrow) previously treated unsuccessfully with steroid medications in adults and children 12 years of age. It is also used for treating chronic graft versus host disease in adults and children 12 years of age and older who were treated unsuccessfully with 1 or 2 other systemic treatments. Jakavi 10mg Tablet works by blocking the signals that cause cancer cells to multiply. Do not take this medicine if you are allergic to ruxolitinib or any other ingredients in this medicine. Inform your physician priorly if you have or had tuberculosis, hepatitis B or C, liver disease, and kidney problems. The most common adverse effects are dizziness, reduced blood counts, bruising, bleeding, headache, and facial and body swelling. Notify your physician if you are on dialysis.
Active Pharmaceutical Ingredient
Uses
• Myelofibrosis
• Polycythemia vera
• Acute-graft-versus host disease
• Chronic-graft-versus host disease
Benefits
Ruxolitinib, a kinase inhibitor, inhibits dysregulated Janus Associated Kinase (JAK) 1 and JAK2 signaling associated with myelofibrosis and polycythemia vera. By blocking certain enzymes, this medicine can reduce the serious risk of blood or vascular complications in myelofibrosis and polycythemia vera. In GVHD, it reduces the signs and symptoms, improving the disease and survival of transplanted cells.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Most Common Side Effects
• Low red and white blood cell counts
• Low platelet counts
• Dizziness, headache
• Bruising
• Diarrhea
• Infections including viral infection
• Swelling in the face and body
• Fatigue or tiredness
Common Side Effects
• Severe infections like hepatitis B
• Anemia
• Bleeding
How To Use
Your doctor will decide the dose and duration of Jakavi 10mg Tablet based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water.
Safety Advice
• Breast Feeding: Breastfeeding is not recommended in patients taking Jakavi 10mg Tablet because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment and for 2 weeks after the last dose.
• Alcohol: It is unknown whether consuming alcohol is safe when taking Jakavi 10mg Tablet. Inform your physician if you are an alcoholic before starting the treatment.
• Liver: Jakavi 10mg Tablet should be administered cautiously in patients with liver problems. Dose adjustments are necessary for patients with liver diseases. Inform your physician if you have any liver disorder before the treatment.
• Lungs: It is unknown whether Jakavi 10mg Tablet can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
• Driving: Do not drive or operate heavy machinery if you feel dizzy after taking Jakavi 10mg Tablet. Consult your doctor for more advice.
• Pregnancy: Do not take Jakavi 10mg Tablet if you are pregnant because this may harm the unborn baby. Inform your physician if you are pregnant, suspecting pregnancy, or planning to get pregnant during the treatment.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.